Literature DB >> 9841601

Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study.

K C Bloch1, L Zwerling, M J Pletcher, J A Hahn, J L Gerberding, S M Ostroff, D J Vugia, A L Reingold.   

Abstract

BACKGROUND: Mycobacterium kansasii, an unusual pathogen in the pre-AIDS era, is increasingly reported to cause infection among patients with HIV infection. Little is known about the epidemiology and clinical implications of M. kansasii infection in the AIDS era.
OBJECTIVE: To compare the incidence, demographic characteristics, and clinical features of M. kansasii infection in HIV-positive and HIV-negative persons.
DESIGN: Population-based laboratory surveillance.
SETTING: Three counties in northern California. PATIENTS: All persons who had a positive culture for M. kansasii between 1 January 1992 and 31 December 1996. MEASUREMENTS: Cumulative incidence rates were calculated for each year by dividing the number of adult patients by the annual estimated adult population. Demographic and socioeconomic data for a single county were obtained by linkage with the 1990 U.S. Census report.
RESULTS: 270 patients (69.3% of whom were HIV positive) were identified, for an incidence of 2.4 cases per 100,000 adults per year (95% CI, 2.1 to 2.7), 115 cases per 100,000 HIV-positive persons per year (CI, 99 to 133), and 647 cases per 100,000 persons with AIDS per year (CI, 554 to 751). Indicators of lower socioeconomic status were common among patients: Median incomes were $32,317 in census tracts in which cases were identified and $38,048 in census tracts without cases (P = 0.001), and 35.7% of patients had unstable housing situations. Ninety-four percent of cases were from respiratory isolates, and 87.5% of patients had evidence of infection. Persons with HIV infection differed from those without HIV infection with respect to mycobacteremia (9.6% compared with 0%; P = 0.001), need for hospitalization (77.4% compared with 51.9%; P < 0.001), and smear positivity (41.7% compared with 20.7%; P = 0.005). Chronic diseases were common among HIV-negative persons; however, 40.3% had no predisposing medical condition.
CONCLUSIONS: Mycobacterium kansasii isolation is more common in HIV-positive persons, but most patients with M. kansasii infection have clinical and radiologic evidence of infection regardless of HIV status. Persons infected with HIV and M. kansasii have a higher rate of hospitalization and a greater burden of organisms. A possible association with poverty suggests mechanisms of transmission and requires further study.

Entities:  

Mesh:

Year:  1998        PMID: 9841601     DOI: 10.7326/0003-4819-129-9-199811010-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  39 in total

1.  Evaluation of the BACTEC MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical specimens and for species identification by DNA AccuProbe.

Authors:  F Alcaide; M A Benítez; J M Escribà; R Martín
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene.

Authors:  F Brunello; M Ligozzi; E Cristelli; S Bonora; E Tortoli; R Fontana
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

3.  Nontuberculous Mycobacterial Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

4.  Evaluation of a modified single-enzyme amplified-fragment length polymorphism technique for fingerprinting and differentiating of Mycobacterium kansasii type I isolates.

Authors:  Ayman Gaafar; M Josebe Unzaga; Ramón Cisterna; Felicitas Elena Clavo; Elena Urra; Rafael Ayarza; Gloria Martín
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 5.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

6.  Clofazimine for the Treatment of Mycobacterium kansasii.

Authors:  Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience.

Authors:  N Maliwan; J R Zvetina
Journal:  Postgrad Med J       Date:  2005-08       Impact factor: 2.401

8.  Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey.

Authors:  Caroline Taillard; Gilbert Greub; Rainer Weber; Gaby E Pfyffer; Thomas Bodmer; Stefan Zimmerli; Reno Frei; Stefano Bassetti; Peter Rohner; Jean-Claude Piffaretti; Enos Bernasconi; Jacques Bille; Amalio Telenti; Guy Prod'hom
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

9.  Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.

Authors:  Moti Chapagain; Tawanda Gumbo; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 10.  Other HIV-associated pneumonias.

Authors:  Jakrapun Pupaibool; Andrew H Limper
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.